Hepatitis C Measures
These measures are used to submit data using the AGA Registry for a potential reimbursement bonus through the CMS Physician Quality Reporting System (PQRS).
- Hep C-84: Ribonucleic Acid (RNA) Testing Before Initiating Treatment
- Hep C-85: Hepatitis C: HCV Genotype Testing Prior to Treatment
- Hep C-86: Hepatitis C: Antiviral Treatment Prescribed
- Hep C-87: Hepatitis C: Ribonucleic Acid (RNA) Testing at Week 12 of Treatment
- Hep C-89: Hepatitis C: Counseling Regarding Risk of Alcohol Consumption
- Hep C-90: Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy
- Hep C-183: Hepatitis C: Hepatitis A Vaccination in Patients with HCV
- Hep C-184: Hepatitis C: Hepatitis B Vaccination in Patients with HCV
Hep C-84: Ribonucleic Acid (RNA) Testing Before Initiating Treatment
Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom quantitative HCV RNA testing was performed within 6 months prior to initiation of antiviral treatment.
Hep C-85: Hepatitis C: HCV Genotype Testing Prior to Treatment
Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom HCV genotype testing was performed prior to initiation of antiviral treatment.
Hep C-86: Hepatitis C: Antiviral Treatment Prescribed
Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who were prescribed peginterferon and ribavirin therapy within the 12-month reporting period.
Hep C-87: Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment
Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom quantitative HCV RNA testing was performed at 12 weeks from the initiation of antiviral treatment.
Hep C-89: Hepatitis C: Counseling Regarding Risk of Alcohol Consumption
Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who were counseled about the risks of alcohol use at least once within 12-months.
Hep C-90: Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy
Percentage of female patients aged 18 through 44 years and all men aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment who were counseled regarding contraception prior to the initiation of treatment.
Hep C-183: Hepatitis C: Hepatitis A Vaccination in Patients with HCV
Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who received at least one injection of hepatitis A vaccine, or who have documented immunity to hepatitis A.
Hep C-184. Hepatitis C: Hepatitis B Vaccination in Patients with HCV
Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who received at least one injection of hepatitis B vaccine, or who have documented immunity to hepatitis B.
